


Figure 1


BEST AVAILABLE COPY

Figure 2A




BEST AVAILABLE COPY

Figure 2B




BEST AVAILABLE COPY

Figure 3




BEST AVAILABLE COPY


Figure 4




IL2/PHA-p
 CD4+ EGFP+: 84.5%
 MF: 1920




ICD3/ICD28
 CD4+ EGFP+: 96%
 MF: 5450




IL2/PHA-P
 CD4+ EGFP+: 80.95%
 MF: 1110



ICD3/ICD28
 CD4+ EGFP+: 95.5%
 MF: 5259




IL2/PHA-P
 CD4+ EGFP+: 70.2%
 MF: 863



ICD3/ICD28
 CD4+ EGFP+: 95.4%
 MF: 5346

BEST AVAILABLE COPY

1st wk: CD3/CD28
 2nd wk: IL2
 CD4+ EGFP+: 92.8%
 MF: 3054



1st wk: IL2/PHA-P
 2nd wk: IL2
 CD4+ EGFP+: 75.3%
 MF: 204





Figure 5

PN2CGFP @ MOI 20
 CD4+ EGFP+: 78.2%
 MF: 1966



PN1(cp)CGFP @ MOI20
 CD4+ EGFP+: 77.1%
 MF: 1591




Figure 6





Figure 7

Figure 8



BEST AVAILABLE COPY




Figure 9




Figure 10

BEST AVAILABLE COPY




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16A




Figure 16B




Figure 16C




Figure 17




Figure 18




Figure 19




Figure 20

BEST AVAILABLE COPY

- **Anti HIV drugs**
 - 2-8 binding sites




**Number of
Mutations
Needed for
Resistance**

Small

**Ability to Cause
Disease**

High

- **Long antisense RNA**
 - 937 binding sites




Large

Low


**HIV either gets destroyed by antisense or it mutates to levels where the virus
is not fit to cause disease**

Figure 21

BEST AVAILABLE COPY




**Fluorescent Microscopic
View of GFP-expressing
vector (Humeau et al.
Mol Ther, 2004)**



Control

0%



>99%

+ vector-EGFP

Figure 22




Figure 23




Figure 24




Figure 25

Table 1. Baseline characteristics of HIV subjects

Characteristics	#1 RB	#2 JFJ	#3 RAG	#4 AJ	#5 JF
Age	41	44	40	27	45
Gender	M	M	M	M	M
Ethnic Group	Caucasian	Caucasian	African American	African American	Caucasian
Mean viral load	188,500	54,100	46,150	54,213	19,972
Mean CD4 counts	228	316	241	308	220
HIV Infection (Yrs)	15	15	15	10	9
Discontinued Therapy	6 NRTI + 2 NNRTI + 5 PI	5 NRTI + 4 PI	6 NRTI + 1 PI	4 NRTI + 2 NNRTI + 1 PI	4 NRTI + 1 NNRTI + 1 PI
Current Therapy	2 NRTI + 2PI	3 NRTI + 1 NNRTI + 1 PI	None	2 NRTI + 1 NRTI	2 NRTI + 1 PI

Figure 26

BEST AVAILABLE COPY




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31




Figure 32

Parameter	Phase I Production	Phase II Production
Media	with 10% FBS	with 5% FBS
Transfection	individual cell factory per bag	8 cell factories per bag
Nunc Cell Factories	16	32
Harvest Collections	2	3
Harvest Volume	~35 L	~ 105L
Collections Mode	Individual NCF	8 NCF per bag
Clarification Filters	2 ft ²	5 ft ²
Concentration	~40 fold	~ 100 fold
Chromatography	4 separate 1L columns	2 serially connected 5L columns
Final volume	~1.2 L	~ 2.5 L

Figure 33




Figure 34

UPenn Phase 1 Cell Product	VIRxSYS Phase 2 Development Lots
CD4+ Cells: 56%, Abs. 3.06×10^8 (52 % recovery)	CD4+ purity: 97.62%, Abs. 3.42×10^9 (47.7% recovery)
CD4+ Cells: 52.2%, Abs. 4.38×10^8 (48% recovery)	CD4+ purity: 97.4%, Abs. 1.48×10^9 (40.5% recovery)
CD4+ Cells: 23%, Abs. 1.67×10^8 (26% recovery)	CD4+ purity: 91.77%, Abs. 2.05×10^9 (48.8% recovery)
CD4+ Cells: 33.4%, Abs. 2.93×10^8 (30% recovery)	
CD4+ Cells: 19.5 %, Abs. 1.77×10^8 (23% recovery)	
Average CD4+purity: 36.82% (range 19.5-56%)	Average CD4+ purity: 95.6% (recovery 91.77-97.62%)

Figure 35

Phase I Cell Product		Phase II Development Lots	
Subject Study ID	Vector copy number per cell	Process Run #	Vector copy number per cell
001-022 J-K	1.20	1	2.80
001-017 A-J	4.10	2	1.19
001-010 RAG	0.98	3	1.48
001-001 JFJ	1.80		
001-002 R-B	2.3		
Average	2.08		1.82

Figure 36

BEST AVAILABLE COPY

Phase I Cell Product		Phase II Development Lots	
Subject Study ID	Total Cells / Fold Expansion	Process Run #	Total Cells / Fold Expansion
001-022 J-K	15.8x10 ⁹ / 65	1	52.3x10 ⁹ / 28.6
001-017 A-J	20.6x10 ⁹ / 40	2	104x10 ⁹ / 58.8
001-010 RAG	6.8x10 ⁹ / 25	3	96.6x10 ⁹ / 63
001-001 JFJ	11.5x10 ⁹ / 32	4	87.5x10 ⁹ / 63.2
001-002 R-B	15.2x10 ⁹ / 66		
Average	14x10⁹ / 45.6		85.1x10⁹ / 53.4

Figure 37

BEST AVAILABLE COPY